Human papillomavirus type 11 L1 capsid protein antigen
- Generic Name
- Human papillomavirus type 11 L1 capsid protein antigen
- Brand Names
- Gardasil, Gardasil 9
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- Z845VHQ61P
- Background
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.
The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.
- Associated Conditions
- Human Papillomavirus (HPV) Infections, Infection caused by human papillomavirus type 11
- Associated Therapies
- -
Gardasil Gains Ground: Merck's HPV Vaccine for Men Approved in China
China's approval of Merck's HPV vaccine, Gardasil, for men marks a significant opportunity to boost Merck's performance in China, despite challenges from anti-corruption measures and declining sales among women.
Merck's GARDASIL® Receives Expanded Approval for HPV Prevention in Males 9-26 in China
Merck announced China's NMPA approved GARDASIL® for males 9-26 to prevent HPV-related cancers and diseases, marking the first HPV vaccine for males in China. GARDASIL targets anal cancers, genital warts, and precancerous lesions caused by specific HPV types. Merck emphasizes its commitment to global HPV vaccine supply and access.
Merck Gets China Nod on HPV Shot for Men Amid Sales Expansion
China approved Merck's HPV vaccine, Gardasil, for men, targeting prevention of anal cancer and genital warts, expanding the market beyond women.
Merck sets sights on Epstein-Barr virus jab with Opko deal
Merck & Co. licenses ModeX Therapeutics' EBV vaccine candidate, MDX-2201, for up to $922.5M plus royalties, taking over clinical development. EBV, infecting 95% of people, can trigger cancers and multiple sclerosis. ModeX's nanoparticle vaccine targets four proteins for cell entry, showing promise in animal studies. The deal follows Opko's $300M acquisition of ModeX.
Merck to End Development of Two Cancer Candidates: Time to Sell?
Merck discontinues development of cancer candidates vibostolimab and favezelimab, impacting KeyVibe and KEYFORM programs. Despite setbacks, Keytruda remains Merck's top revenue driver, with strong sales in early-stage lung cancer. Merck focuses on Keytruda's long-term growth through innovative combinations and partnerships. However, reliance on Keytruda and declining Gardasil sales in China raise concerns. Merck's stock underperforms, yet its valuation and pipeline suggest potential for long-term investors.
Cervical Cancer Deaths Fell Dramatically After Advent of HPV Vaccine
A study shows a 62% drop in cervical cancer deaths over the last decade, likely due to HPV vaccination. The study tracked U.S. deaths among women under 25 from 1990 to 2021, finding a significant decline in deaths post-2019, from 50-60 deaths every three years to 13. Despite this, only about 60% of 13-to-15-year-olds have received the recommended HPV doses, raising concerns about future cervical cancer rates.
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly's share price rose 37% due to Zepbound approval, while Pfizer fell 10.77% under activist investor pressure. Merck dropped 7.46% as Keytruda nears patent expiration. Amgen's share price declined 5.92% after MariTide's Phase II results. Vertex's share price increased 13.35% with CF drug success. Novo Nordisk's share price rose 2.76% with Wegovy's market impact.
Top 10 pharmaceutical companies in the world
Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap
The biopharmaceutical sector rebounded in Q3 2024, with top 20 companies seeing a 2% increase in market capitalization to $4.3 trillion. Bristol-Myers Squibb led with a 24.6% surge, driven by FDA approval of Cobenfy. Gilead Sciences rose 22.1% due to accelerated approvals for Livdelzi and Trodelvy. Sanofi's market cap jumped 19.2% on Dupixent's success. AbbVie gained 15.2% from immunology drugs. Alnylam Pharmaceuticals and Roche Holdings also saw significant growth. Novo Nordisk, Eli Lilly, and Merck faced declines.
Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of drug approvals
Top 20 biopharmaceutical companies saw a 2% market cap increase in Q3 2024, driven by FDA approvals and strategic alliances. Bristol Myers Squibb led with a 24.6% growth, fueled by Cobenfy's approval and a $3.5bn deal with Prime Medicine. Gilead Sciences and Sanofi also grew significantly due to new drug approvals. Despite some declines, industry recovery is expected, supported by Federal Reserve interest rate cuts.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath